Skip Navigation LinksHome > September 2014 - Volume 26 - Issue 5 > Editorial introductions
Text sizing:
A
A
A
Current Opinion in Oncology:
doi: 10.1097/CCO.0000000000000116
Editorial Introductions

Editorial introductions

Section Editor(s): Coiffier, Bertrand; Michallet, Anne-Sophie; Gore, Martin

Free Access

Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.

Back to Top | Article Outline

SECTION EDITORS

Bertrand Coiffier

Bertrand Coiffier is Professor of Hematology at the Department of Hematology, Hospices Civils de Lyon and the University Claude Bernard, Lyon, France. After having specialized in hematology, Professor Coiffier has held a number of positions at the Hematology Department of the Edouard-Herriot Hospital, Lyon and then the Centre Hospitalier Lyon-Sud, Pierre-Benite. He is a member of several international societies, including the American Society of Hematology, the American Society of Clinical Oncology, the International Society for Medical Oncology, the European Haematology Association, and the European Society for Medical Oncology. Professor Coiffier is a founding member of the Group d’Etude des Lymphomes de l’Adulte (GELA) and has been President of the GELA since 2006. He has published over 300 papers in peer-reviewed journals.

Back to Top | Article Outline
Anne-Sophie Michallet

Anne-Sophie Michallet is a Doctor of Hematology at the Department of Hematology, Hospices Civils de Lyon and the University Claude Bernard, Lyon, France. After having specialized in hematology, she focused on lymphoproliferative disorders. She is a member of the French Group of Chronic Lymphocyic Leukemia (GFCLL and GOELAMS), the Group d’Etude des Lymphomes de l’Adulte (GELA); and a member of the société française de greffe de moelle (SFGM-TC).

Back to Top | Article Outline
Martin Gore

Image Tools

Professor Martin Gore is the Medical Director of the Royal Marsden Hospital and Professor of Cancer Medicine at the Institute of Cancer Research, UK. He qualified in medicine at St Bartholomew's Hospital, London, UK, and spent time in general practice before training in general internal medicine at University College Hospital, London, UK. He joined the Ludwig Institute of Cancer Research in 1981 where he worked as a clinical scientist and was awarded a PhD for his work on breast cancer.

Professor Gore serves on The Commission on Human Medicines, is the founder Co-Patron of the Rarer Cancers Foundation and was a founder Senior Investigator of the UK's National Institute for Health Research.

He previously chaired the Department of Health's Gene Therapy Advisory Committee is a past President of the UK Melanoma Study Group and a past Chair of the National Cancer Research Institute's Melanoma Clinical Studies Group. He has served on the Health and Safety Executive's Scientific Advisory Committee on Genetically Modified Organisms, the Council of the International Gynaecologic Cancer Society, the Programme Committee of the Annual Meeting of the American Society of Clinical Oncology and he was co-founder of the European International Kidney Cancer Symposium. He is a Medical Advisor to the US-based patient advocacy group the Kidney Cancer Association who awarded him the Eugene P. Schonfeld Memorial Lecturership in 2014, the first non-US recipient.

He is the editor of the Gynaecological Cancer Section of Current Opinion in Oncology and has served on the editorial board of several journals including the Journal of Clinical Oncology. He has published over 400 articles and edited eight textbooks.

Professor Gore's main research interests are the development of novel therapeutics in ovarian cancer, melanoma and renal cell carcinoma, particularly in the area of immunotherapy, gene therapy and targeted agents.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login